“Yes. I would just say on VBP, that can affect the quarter at an OU level, but we don't necessarily expect it to affect total Medtronic.”

In context

“re than we had in the past, and they're able to allocate resources, I think, more effectively to -- because the health care is local and these markets have different emphasis on different clinical areas. And some have more cath labs than others, and that makes a difference, for example. And so with our emerging market leaders able to have more influence and control over the resources that's helped accelerate our growth as well. So I think the fundamentals are back, especially in China. Our -- some changes we've made to our -- like our model and our incentives have helped as well and our continued investment in value products. You add all that up and I see this as a continued strength and a continued source of growth for the company over a decade plus. Karen, anything else? Karen Parkhill: Yes. I would just say on VBP, that can affect the quarter at an OU level, but we don't necessarily expect it to affect total Medtronic. Joshua Jennings: Great. Just maybe one quick follow-up. Any product launches that we should be thinking about as we build out our -- update our models for fiscal '25, particularly in these emerging markets, but China specifically? Thanks. Geoff Martha: Well, in China, specifically, we did just get approval for Ardian. So that will take some time to get into all the hospitals, but we think that's going to do well. Our -- we think our CST business, again separate from, I think, to some of the trends you're seeing in the US. We've got a strong local portfolio there and a nice flywheel of local innovation. So a local version of Mazor that's coming out a local version of our cell station navigation that's coming out. So I see strength there. And then we've also started local manufacturing of s”